Global Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2029
The Global Motion Sickness Treatment Market size is expected to reach $481 Million by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
Motion sickness is a condition that arises when the brain is unable to interpret the information received from the eyes, ears, and body. Frequent movement, whether in a vehicle, aircraft, watercraft, or a recreational attraction, can induce discomfort, perspiration, or nausea. Certain individuals experience nausea and may regurgitate. Motion sickness is a condition that occurs when traveling by car, sea, or air, causing discomfort and nausea.
When driving a vehicle, the visual senses perceive the surroundings and detect motion. The inner ears are responsible for detecting movement. The body's muscles and joints perceive a state of stillness while seated. The brain senses a lack of coherence between these messages, causing motion sickness. Various factors can induce motion sickness, including amusement park attractions and virtual reality simulations. Reading while in transit, using transportation options like boats, cars, buses, trains, and planes. Also, too much consumption of entertainment media such as movies and video games can lead to motion sickness.
Motion sickness may occur unexpectedly. Individuals may exhibit symptoms without prior warning, including perspiration caused by a sudden drop in body temperature. Dizziness, fatigue, headache, irritability, difficulty in maintaining focus. Symptoms of potential gastrointestinal distress. Fair complexion. Symptoms of respiratory distress may include rapid breathing or gasping for air.
COVID-19 Impact Analysis
During the COVID-19 pandemic, the number of tours and journeys throughout the world declined, which led to a subsequent drop in sales of motion sickness medication. As a result, the market for motion sickness therapy was significantly damaged. In addition, the pandemic was responsible for the shutdown or suspension of production operations in most industrial units around the world. This had an effect, to some degree, on the production of motion sickness treatments. The healthcare industry has experienced a disruption in workflows due to the COVID-19 pandemic.
Market Growth Factors
Rising Tourism Industry
The travel and tourism industry are increasing due to the increasing affordability of air travel, enhanced accessibility to remote and picturesque destinations, and a surge in disposable income. The travel and tourism sector has been strengthened by the substantial development of transportation facilities and infrastructure. There is a growing demand among millennial travelers for distinctive and exclusive experiences and also ecotourism is a growing trend in the current scenario. National and international tourism is increasing in almost all parts of the world, and individuals use various types of transportation to reach their destinations, like airplanes, cars, and ships. However, these modes of transportation can cause many travelers’ motion sickness to kick in, which may require treatment and thereby propel the market growth.
Growing Pharma Sector to Provide Enhanced Motion Sickness Medications
The pharmaceutical industry has experienced significant changes due to the introduction of innovative technologies and streamlined manufacturing processes that are both cost-effective and efficient. Furthermore, the rise in investment flow within this sector has positively impacted sector growth. Integrating robotic technology and AI leads to decreased manufacturing floor downtime and minimizes product waste. The development of the pharma sector and its technological advancement is expected to provide more efficient and cost-effective medications for motion sickness and thereby increase their adoption, driving the market growth for motion sickness treatment.
Market Restraining Factors
Associated Side Effects of Motion Sickness Medication
H1-antihistamines in certain professions, such as astronauts, are limited due to side effects that can affect cognitive function, memory, psychomotor performance, drowsiness, fatigue, and dizziness. Additional documented negative outcomes comprise dystonia, dyskinesia, restlessness, disorientation, delusions, and potential harm to the heart. Furthermore, the anticholinergic activity of first-generation antihistamines may result in adverse effects, including but not limited to dry mouth, blurred vision, dilated pupils, and urinary retention. Hence, with the side effects of antihistamines and anticholinergics two most prominent drug classes for the treatment of motion sickness can decrease the adoption of these treatment options and, thereby, hamper the market growth of motion sickness treatment.
Drug Class Outlook
Based on drug class, the motion sickness treatment market is segmented into antihistamines, anticholinergics and others. The antihistamines segment dominated the motion sickness treatment market with maximum revenue share in 2022. This is because antihistamines are a cost-effective and readily available solution for reducing motion sickness. This is due to a rise in the prevalence of motion sickness among travelers. Furthermore, the segment's growth is being propelled by the presence of major players who provide antihistamine medications to prevent and treat motion sickness.
Route of Administration Outlook
On the basis of route of administration, the motion sickness treatment market is divided into oral and others. The others segment procured a substantial revenue share in the motion sickness treatment market in 2022. This is due to the rise in the usage of transdermal patches for motion sickness treatment and prevention, which is the reason behind this trend. In addition, these transdermal patches provide benefits such as user-friendliness, controlled release mechanism, and extended efficacy in comparison to traditional medications.
Distribution Channel Outlook
By distribution channel, the motion sickness treatment market is classified into drug store & retail pharmacies, online pharmacies and hospital pharmacies. The drug store & retail pharmacies segment witnessed the largest revenue share in the motion sickness treatment market in 2022. This is because pharmacies and drug stores have been the traditional means of distributing motion sickness medication to consumers. These establishments offer these products at discounted prices. Drug stores and retail pharmacies are the preferred choice for purchasing motion sickness medications among most of the population.
Regional Outlook
Region-wise, the motion sickness treatment market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region registered the highest revenue share in the motion sickness treatment market in 2022. North America's dominant position in the healthcare industry can be attributed to its robust healthcare infrastructure and government backing for high-quality healthcare. As a result, North America has a significant number of prominent market players who provide top-notch motion sickness medications.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Scope of the Study
Market Segments covered in the Report:
By Drug Class
Antihistamines
Anticholinergics
Others
By Route of Administration
Oral
Others
By Distribution Channel
Drug Store & Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Companies Profiled
Viatris, Inc.
Teva Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals, Inc.
Baxter International, Inc.
Novartis AG
Abbott Laboratories
Sun Pharmaceutical Industries Ltd.
Zydus Lifesciences Ltd.
Prestige Consumer Healthcare, Inc.
WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Unique Offerings from KBV Research
Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Motion Sickness Treatment Market, by Drug Class
- 1.4.2 Global Motion Sickness Treatment Market, by Route of Administration
- 1.4.3 Global Motion Sickness Treatment Market, by Distribution Channel
- 1.4.4 Global Motion Sickness Treatment Market, by Geography
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. Global Motion Sickness Treatment Market by Drug Class
- 3.1 Global Antihistamines Market by Region
- 3.2 Global Anticholinergics Market by Region
- 3.3 Global Others Market by Region
- Chapter 4. Global Motion Sickness Treatment Market by Route of Administration
- 4.1 Global Oral Market by Region
- 4.2 Global Others Market by Region
- Chapter 5. Global Motion Sickness Treatment Market by Distribution Channel
- 5.1 Global Drug Store & Retail Pharmacies Market by Region
- 5.2 Global Hospital Pharmacies Market by Region
- 5.3 Global Online Pharmacies Market by Region
- Chapter 6. Global Motion Sickness Treatment Market by Region
- 6.1 North America Motion Sickness Treatment Market
- 6.1.1 North America Motion Sickness Treatment Market by Drug Class
- 6.1.1.1 North America Antihistamines Market by Country
- 6.1.1.2 North America Anticholinergics Market by Country
- 6.1.1.3 North America Others Market by Country
- 6.1.2 North America Motion Sickness Treatment Market by Route of Administration
- 6.1.2.1 North America Oral Market by Country
- 6.1.2.2 North America Others Market by Country
- 6.1.3 North America Motion Sickness Treatment Market by Distribution Channel
- 6.1.3.1 North America Drug Store & Retail Pharmacies Market by Country
- 6.1.3.2 North America Hospital Pharmacies Market by Country
- 6.1.3.3 North America Online Pharmacies Market by Country
- 6.1.4 North America Motion Sickness Treatment Market by Country
- 6.1.4.1 US Motion Sickness Treatment Market
- 6.1.4.1.1 US Motion Sickness Treatment Market by Drug Class
- 6.1.4.1.2 US Motion Sickness Treatment Market by Route of Administration
- 6.1.4.1.3 US Motion Sickness Treatment Market by Distribution Channel
- 6.1.4.2 Canada Motion Sickness Treatment Market
- 6.1.4.2.1 Canada Motion Sickness Treatment Market by Drug Class
- 6.1.4.2.2 Canada Motion Sickness Treatment Market by Route of Administration
- 6.1.4.2.3 Canada Motion Sickness Treatment Market by Distribution Channel
- 6.1.4.3 Mexico Motion Sickness Treatment Market
- 6.1.4.3.1 Mexico Motion Sickness Treatment Market by Drug Class
- 6.1.4.3.2 Mexico Motion Sickness Treatment Market by Route of Administration
- 6.1.4.3.3 Mexico Motion Sickness Treatment Market by Distribution Channel
- 6.1.4.4 Rest of North America Motion Sickness Treatment Market
- 6.1.4.4.1 Rest of North America Motion Sickness Treatment Market by Drug Class
- 6.1.4.4.2 Rest of North America Motion Sickness Treatment Market by Route of Administration
- 6.1.4.4.3 Rest of North America Motion Sickness Treatment Market by Distribution Channel
- 6.2 Europe Motion Sickness Treatment Market
- 6.2.1 Europe Motion Sickness Treatment Market by Drug Class
- 6.2.1.1 Europe Antihistamines Market by Country
- 6.2.1.2 Europe Anticholinergics Market by Country
- 6.2.1.3 Europe Others Market by Country
- 6.2.2 Europe Motion Sickness Treatment Market by Route of Administration
- 6.2.2.1 Europe Oral Market by Country
- 6.2.2.2 Europe Others Market by Country
- 6.2.3 Europe Motion Sickness Treatment Market by Distribution Channel
- 6.2.3.1 Europe Drug Store & Retail Pharmacies Market by Country
- 6.2.3.2 Europe Hospital Pharmacies Market by Country
- 6.2.3.3 Europe Online Pharmacies Market by Country
- 6.2.4 Europe Motion Sickness Treatment Market by Country
- 6.2.4.1 Germany Motion Sickness Treatment Market
- 6.2.4.1.1 Germany Motion Sickness Treatment Market by Drug Class
- 6.2.4.1.2 Germany Motion Sickness Treatment Market by Route of Administration
- 6.2.4.1.3 Germany Motion Sickness Treatment Market by Distribution Channel
- 6.2.4.2 UK Motion Sickness Treatment Market
- 6.2.4.2.1 UK Motion Sickness Treatment Market by Drug Class
- 6.2.4.2.2 UK Motion Sickness Treatment Market by Route of Administration
- 6.2.4.2.3 UK Motion Sickness Treatment Market by Distribution Channel
- 6.2.4.3 France Motion Sickness Treatment Market
- 6.2.4.3.1 France Motion Sickness Treatment Market by Drug Class
- 6.2.4.3.2 France Motion Sickness Treatment Market by Route of Administration
- 6.2.4.3.3 France Motion Sickness Treatment Market by Distribution Channel
- 6.2.4.4 Russia Motion Sickness Treatment Market
- 6.2.4.4.1 Russia Motion Sickness Treatment Market by Drug Class
- 6.2.4.4.2 Russia Motion Sickness Treatment Market by Route of Administration
- 6.2.4.4.3 Russia Motion Sickness Treatment Market by Distribution Channel
- 6.2.4.5 Spain Motion Sickness Treatment Market
- 6.2.4.5.1 Spain Motion Sickness Treatment Market by Drug Class
- 6.2.4.5.2 Spain Motion Sickness Treatment Market by Route of Administration
- 6.2.4.5.3 Spain Motion Sickness Treatment Market by Distribution Channel
- 6.2.4.6 Italy Motion Sickness Treatment Market
- 6.2.4.6.1 Italy Motion Sickness Treatment Market by Drug Class
- 6.2.4.6.2 Italy Motion Sickness Treatment Market by Route of Administration
- 6.2.4.6.3 Italy Motion Sickness Treatment Market by Distribution Channel
- 6.2.4.7 Rest of Europe Motion Sickness Treatment Market
- 6.2.4.7.1 Rest of Europe Motion Sickness Treatment Market by Drug Class
- 6.2.4.7.2 Rest of Europe Motion Sickness Treatment Market by Route of Administration
- 6.2.4.7.3 Rest of Europe Motion Sickness Treatment Market by Distribution Channel
- 6.3 Asia Pacific Motion Sickness Treatment Market
- 6.3.1 Asia Pacific Motion Sickness Treatment Market by Drug Class
- 6.3.1.1 Asia Pacific Antihistamines Market by Country
- 6.3.1.2 Asia Pacific Anticholinergics Market by Country
- 6.3.1.3 Asia Pacific Others Market by Country
- 6.3.2 Asia Pacific Motion Sickness Treatment Market by Route of Administration
- 6.3.2.1 Asia Pacific Oral Market by Country
- 6.3.2.2 Asia Pacific Others Market by Country
- 6.3.3 Asia Pacific Motion Sickness Treatment Market by Distribution Channel
- 6.3.3.1 Asia Pacific Drug Store & Retail Pharmacies Market by Country
- 6.3.3.2 Asia Pacific Hospital Pharmacies Market by Country
- 6.3.3.3 Asia Pacific Online Pharmacies Market by Country
- 6.3.4 Asia Pacific Motion Sickness Treatment Market by Country
- 6.3.4.1 China Motion Sickness Treatment Market
- 6.3.4.1.1 China Motion Sickness Treatment Market by Drug Class
- 6.3.4.1.2 China Motion Sickness Treatment Market by Route of Administration
- 6.3.4.1.3 China Motion Sickness Treatment Market by Distribution Channel
- 6.3.4.2 Japan Motion Sickness Treatment Market
- 6.3.4.2.1 Japan Motion Sickness Treatment Market by Drug Class
- 6.3.4.2.2 Japan Motion Sickness Treatment Market by Route of Administration
- 6.3.4.2.3 Japan Motion Sickness Treatment Market by Distribution Channel
- 6.3.4.3 India Motion Sickness Treatment Market
- 6.3.4.3.1 India Motion Sickness Treatment Market by Drug Class
- 6.3.4.3.2 India Motion Sickness Treatment Market by Route of Administration
- 6.3.4.3.3 India Motion Sickness Treatment Market by Distribution Channel
- 6.3.4.4 South Korea Motion Sickness Treatment Market
- 6.3.4.4.1 South Korea Motion Sickness Treatment Market by Drug Class
- 6.3.4.4.2 South Korea Motion Sickness Treatment Market by Route of Administration
- 6.3.4.4.3 South Korea Motion Sickness Treatment Market by Distribution Channel
- 6.3.4.5 Singapore Motion Sickness Treatment Market
- 6.3.4.5.1 Singapore Motion Sickness Treatment Market by Drug Class
- 6.3.4.5.2 Singapore Motion Sickness Treatment Market by Route of Administration
- 6.3.4.5.3 Singapore Motion Sickness Treatment Market by Distribution Channel
- 6.3.4.6 Malaysia Motion Sickness Treatment Market
- 6.3.4.6.1 Malaysia Motion Sickness Treatment Market by Drug Class
- 6.3.4.6.2 Malaysia Motion Sickness Treatment Market by Route of Administration
- 6.3.4.6.3 Malaysia Motion Sickness Treatment Market by Distribution Channel
- 6.3.4.7 Rest of Asia Pacific Motion Sickness Treatment Market
- 6.3.4.7.1 Rest of Asia Pacific Motion Sickness Treatment Market by Drug Class
- 6.3.4.7.2 Rest of Asia Pacific Motion Sickness Treatment Market by Route of Administration
- 6.3.4.7.3 Rest of Asia Pacific Motion Sickness Treatment Market by Distribution Channel
- 6.4 LAMEA Motion Sickness Treatment Market
- 6.4.1 LAMEA Motion Sickness Treatment Market by Drug Class
- 6.4.1.1 LAMEA Antihistamines Market by Country
- 6.4.1.2 LAMEA Anticholinergics Market by Country
- 6.4.1.3 LAMEA Others Market by Country
- 6.4.2 LAMEA Motion Sickness Treatment Market by Route of Administration
- 6.4.2.1 LAMEA Oral Market by Country
- 6.4.2.2 LAMEA Others Market by Country
- 6.4.3 LAMEA Motion Sickness Treatment Market by Distribution Channel
- 6.4.3.1 LAMEA Drug Store & Retail Pharmacies Market by Country
- 6.4.3.2 LAMEA Hospital Pharmacies Market by Country
- 6.4.3.3 LAMEA Online Pharmacies Market by Country
- 6.4.4 LAMEA Motion Sickness Treatment Market by Country
- 6.4.4.1 Brazil Motion Sickness Treatment Market
- 6.4.4.1.1 Brazil Motion Sickness Treatment Market by Drug Class
- 6.4.4.1.2 Brazil Motion Sickness Treatment Market by Route of Administration
- 6.4.4.1.3 Brazil Motion Sickness Treatment Market by Distribution Channel
- 6.4.4.2 Argentina Motion Sickness Treatment Market
- 6.4.4.2.1 Argentina Motion Sickness Treatment Market by Drug Class
- 6.4.4.2.2 Argentina Motion Sickness Treatment Market by Route of Administration
- 6.4.4.2.3 Argentina Motion Sickness Treatment Market by Distribution Channel
- 6.4.4.3 UAE Motion Sickness Treatment Market
- 6.4.4.3.1 UAE Motion Sickness Treatment Market by Drug Class
- 6.4.4.3.2 UAE Motion Sickness Treatment Market by Route of Administration
- 6.4.4.3.3 UAE Motion Sickness Treatment Market by Distribution Channel
- 6.4.4.4 Saudi Arabia Motion Sickness Treatment Market
- 6.4.4.4.1 Saudi Arabia Motion Sickness Treatment Market by Drug Class
- 6.4.4.4.2 Saudi Arabia Motion Sickness Treatment Market by Route of Administration
- 6.4.4.4.3 Saudi Arabia Motion Sickness Treatment Market by Distribution Channel
- 6.4.4.5 South Africa Motion Sickness Treatment Market
- 6.4.4.5.1 South Africa Motion Sickness Treatment Market by Drug Class
- 6.4.4.5.2 South Africa Motion Sickness Treatment Market by Route of Administration
- 6.4.4.5.3 South Africa Motion Sickness Treatment Market by Distribution Channel
- 6.4.4.6 Nigeria Motion Sickness Treatment Market
- 6.4.4.6.1 Nigeria Motion Sickness Treatment Market by Drug Class
- 6.4.4.6.2 Nigeria Motion Sickness Treatment Market by Route of Administration
- 6.4.4.6.3 Nigeria Motion Sickness Treatment Market by Distribution Channel
- 6.4.4.7 Rest of LAMEA Motion Sickness Treatment Market
- 6.4.4.7.1 Rest of LAMEA Motion Sickness Treatment Market by Drug Class
- 6.4.4.7.2 Rest of LAMEA Motion Sickness Treatment Market by Route of Administration
- 6.4.4.7.3 Rest of LAMEA Motion Sickness Treatment Market by Distribution Channel
- Chapter 7. Company Profiles
- 7.1 Viatris, Inc.
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental Analysis
- 7.1.4 Research & Development Expense
- 7.2 Teva Pharmaceutical Industries Ltd.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Regional Analysis
- 7.2.4 Research & Development Expenses
- 7.3 Amneal Pharmaceuticals, Inc.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Segmental Analysis
- 7.3.4 Research & Development Expenses
- 7.4 Baxter International, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Segmental Analysis
- 7.4.4 Research & Development Expense
- 7.5 Novartis AG
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Segmental and Regional Analysis
- 7.5.4 Research & Development Expense
- 7.6 Abbott Laboratories
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Segmental and Regional Analysis
- 7.6.4 Research & Development Expense
- 7.6.5 SWOT Analysis
- 7.7 Sun Pharmaceutical Industries Ltd.
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Regional Analysis
- 7.7.4 Research & Development Expenses
- 7.8 Zydus Lifesciences Ltd.
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
- 7.8.5 Recent strategies and developments:
- 7.8.5.1 Trials and Approvals:
- 7.9 Prestige Consumer Healthcare, Inc.
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Segmental and Regional Analysis
- 7.10. WellSpring Pharmaceutical Corporation (Avista Capital Partners)
- 7.10.1 Company Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook